Trial Profile
Reversal of Neuromuscular Blockade with Sugammadex Based on the Residual of Rocuronium in the Body
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2018
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Rocuronium bromide
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 16 Apr 2018 Status changed from active, no longer recruiting to completed.
- 17 Apr 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan.
- 15 Apr 2015 New trial record